Licensed vaccine
CYFENDUS
FDA-licensed vaccine · Emergent Product Development Gaithersburg Inc. · STN 125761
Key facts
| Trade name | CYFENDUS |
|---|---|
| Proper name | Anthrax Vaccine Adsorbed, Adjuvanted |
| Manufacturer | Emergent Product Development Gaithersburg Inc. |
| Submission tracking number (STN) | 125761 |
| Recent FDA documents | Approval History, Letters, Reviews, and Related Documents - CYFENDUS, Demographic Subgroup Information – Anthrax Vaccine Adsorbed, Adjuvanted (CYFENDUS), July 20, 2023 Summary Basis for Regulatory Action - CYFENDUS, Patient Information - CYFENDUS, July 20, 2023 Approval Letter - CYFENDUS, Package Insert - CYFENDUS |
| FDA page updated | Aug 14, 2023 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: